ArticleInternational journal of general medicine2026
Predicting the Impact of ARHGAP33 Gene on Liver Cancer Prognosis Based on Multi-Algorithm Model.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the impact of Rho GTPase-activating protein 33 (ARHGAP33) and its synergistic interaction with SFPQ on the prognosis of hepatocellular carcinoma (HCC) through bioinformatics and experimental research. Materials and Methods: RNA sequencing data from The Cancer Genome Atlas (TCGA) were analyzed to assess ARHGAP33 expression in hepatocellular carcinoma (HCC). Co-expressed genes were identified using WGCNA and GSVA, and integrated into a multi-algorithm consensus prognostic model. Results: The analysis of the TCGA database indicated a marked overexpression of ARHGAP33 mRNA in tissues from hepatocellular carcinoma (LIHC), with a statistically significant finding (P < 0.001). WGCNA revealed that SFPQ is a gene associated with ARHGAP33. In the developed consensus prognostic model, survival analysis using Kaplan-Meier (K-M) alongside the CoxBoost model demonstrated that the overall survival time for patients classified as high-risk was significantly less than that of those classified as low-risk (P < 0.05).The Institutional Review Board at Shihezi University granted ethical approval for this research (Ethics Application No.: KJ2025-290-01). Conclusion: The expression level of ARHGAP33 affects HCC prognosis, and its synergistic overexpression with SFPQ impairs the prognosis of HCC patients. ARHGAP33 could potentially be used as a biomarker for evaluating prognosis in hepatocellular carcinoma (HCC), offering a new theoretical foundation for enhancing HCC outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.